Diebold Nixdorf, Incorporated (NYSE: DBD) Stock Competitors & Peer Comparison

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, SAP has a market cap of 244.1B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while SAP trades at $209.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas SAP's P/E ratio is 28.08. In terms of profitability, DBD's ROE is +0.11%, compared to SAP's ROE of +0.18%. Regarding short-term risk, DBD is more volatile compared to SAP. This indicates higher risk in terms of short-term price fluctuations for DBD.Check SAP's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, CRM has a market cap of 194.9B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while CRM trades at $237.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas CRM's P/E ratio is 17.18. In terms of profitability, DBD's ROE is +0.11%, compared to CRM's ROE of +0.20%. Regarding short-term risk, DBD is more volatile compared to CRM. This indicates higher risk in terms of short-term price fluctuations for DBD.Check CRM's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, SHOP has a market cap of 166.5B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while SHOP trades at $128.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas SHOP's P/E ratio is 81.20. In terms of profitability, DBD's ROE is +0.11%, compared to SHOP's ROE of +0.15%. Regarding short-term risk, DBD is more volatile compared to SHOP. This indicates higher risk in terms of short-term price fluctuations for DBD.Check SHOP's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, UBER has a market cap of 143.5B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while UBER trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas UBER's P/E ratio is 14.75. In terms of profitability, DBD's ROE is +0.11%, compared to UBER's ROE of +0.36%. Regarding short-term risk, DBD is more volatile compared to UBER. This indicates higher risk in terms of short-term price fluctuations for DBD.Check UBER's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, NOW has a market cap of 139.7B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while NOW trades at $135.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas NOW's P/E ratio is 36.80. In terms of profitability, DBD's ROE is +0.11%, compared to NOW's ROE of +0.14%. Regarding short-term risk, DBD is more volatile compared to NOW. This indicates higher risk in terms of short-term price fluctuations for DBD.Check NOW's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, SNOW has a market cap of 114.9B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while SNOW trades at $332.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas SNOW's P/E ratio is 235.20. In terms of profitability, DBD's ROE is +0.11%, compared to SNOW's ROE of -0.54%. Regarding short-term risk, DBD is more volatile compared to SNOW. This indicates higher risk in terms of short-term price fluctuations for DBD.Check SNOW's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, ADP has a market cap of 108.8B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while ADP trades at $271.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas ADP's P/E ratio is 24.48. In terms of profitability, DBD's ROE is +0.11%, compared to ADP's ROE of +0.70%. Regarding short-term risk, DBD is more volatile compared to ADP. This indicates higher risk in terms of short-term price fluctuations for DBD.Check ADP's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, APP has a market cap of 103.5B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while APP trades at $308.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas APP's P/E ratio is 23.68. In terms of profitability, DBD's ROE is +0.11%, compared to APP's ROE of +1.93%. Regarding short-term risk, DBD is less volatile compared to APP. This indicates lower risk in terms of short-term price fluctuations for DBD.Check APP's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, ADBE has a market cap of 100.4B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while ADBE trades at $248.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas ADBE's P/E ratio is 11.07. In terms of profitability, DBD's ROE is +0.11%, compared to ADBE's ROE of +0.63%. Regarding short-term risk, DBD is more volatile compared to ADBE. This indicates higher risk in terms of short-term price fluctuations for DBD.Check ADBE's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, INTU has a market cap of 82.9B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while INTU trades at $303.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas INTU's P/E ratio is 13.16. In terms of profitability, DBD's ROE is +0.11%, compared to INTU's ROE of +0.23%. Regarding short-term risk, DBD is more volatile compared to INTU. This indicates higher risk in terms of short-term price fluctuations for DBD.Check INTU's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, DDOG has a market cap of 81.8B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while DDOG trades at $229.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas DDOG's P/E ratio is 96.20. In terms of profitability, DBD's ROE is +0.11%, compared to DDOG's ROE of +0.05%. Regarding short-term risk, DBD is less volatile compared to DDOG. This indicates lower risk in terms of short-term price fluctuations for DBD.Check DDOG's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, CDNS has a market cap of 77.9B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while CDNS trades at $282.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas CDNS's P/E ratio is 37.57. In terms of profitability, DBD's ROE is +0.11%, compared to CDNS's ROE of +0.23%. Regarding short-term risk, DBD is more volatile compared to CDNS. This indicates higher risk in terms of short-term price fluctuations for DBD.Check CDNS's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, NBIS has a market cap of 53.6B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while NBIS trades at $223.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas NBIS's P/E ratio is -112.33. In terms of profitability, DBD's ROE is +0.11%, compared to NBIS's ROE of +0.01%. Regarding short-term risk, DBD is less volatile compared to NBIS. This indicates lower risk in terms of short-term price fluctuations for DBD.Check NBIS's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, MSTR has a market cap of 50.9B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while MSTR trades at $153.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas MSTR's P/E ratio is -1.58. In terms of profitability, DBD's ROE is +0.11%, compared to MSTR's ROE of -0.61%. Regarding short-term risk, DBD is less volatile compared to MSTR. This indicates lower risk in terms of short-term price fluctuations for DBD.Check MSTR's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, WDAY has a market cap of 50.8B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while WDAY trades at $193.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas WDAY's P/E ratio is 20.07. In terms of profitability, DBD's ROE is +0.11%, compared to WDAY's ROE of +0.17%. Regarding short-term risk, DBD is more volatile compared to WDAY. This indicates higher risk in terms of short-term price fluctuations for DBD.Check WDAY's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, TEAM has a market cap of 50.4B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while TEAM trades at $192.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas TEAM's P/E ratio is 38.48. In terms of profitability, DBD's ROE is +0.11%, compared to TEAM's ROE of -0.04%. Regarding short-term risk, DBD is more volatile compared to TEAM. This indicates higher risk in terms of short-term price fluctuations for DBD.Check TEAM's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, ADSK has a market cap of 46.2B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while ADSK trades at $216.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas ADSK's P/E ratio is 19.64. In terms of profitability, DBD's ROE is +0.11%, compared to ADSK's ROE of +0.53%. Regarding short-term risk, DBD is more volatile compared to ADSK. This indicates higher risk in terms of short-term price fluctuations for DBD.Check ADSK's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, VEEV has a market cap of 42.3B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while VEEV trades at $260.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas VEEV's P/E ratio is 31.24. In terms of profitability, DBD's ROE is +0.11%, compared to VEEV's ROE of +0.14%. Regarding short-term risk, DBD is more volatile compared to VEEV. This indicates higher risk in terms of short-term price fluctuations for DBD.Check VEEV's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, ROP has a market cap of 37.6B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while ROP trades at $372.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas ROP's P/E ratio is 18.29. In terms of profitability, DBD's ROE is +0.11%, compared to ROP's ROE of +0.13%. Regarding short-term risk, DBD is more volatile compared to ROP. This indicates higher risk in terms of short-term price fluctuations for DBD.Check ROP's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, STRC has a market cap of 34B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while STRC trades at $98.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas STRC's P/E ratio is -1.01. In terms of profitability, DBD's ROE is +0.11%, compared to STRC's ROE of -0.61%. Regarding short-term risk, DBD is more volatile compared to STRC. This indicates higher risk in terms of short-term price fluctuations for DBD.Check STRC's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, ANSS has a market cap of 32.9B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while ANSS trades at $374.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas ANSS's P/E ratio is 55.53. In terms of profitability, DBD's ROE is +0.11%, compared to ANSS's ROE of +0.10%. Regarding short-term risk, DBD is more volatile compared to ANSS. This indicates higher risk in terms of short-term price fluctuations for DBD.Check ANSS's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, STRF has a market cap of 30.9B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while STRF trades at $104.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas STRF's P/E ratio is -1.07. In terms of profitability, DBD's ROE is +0.11%, compared to STRF's ROE of -0.61%. Regarding short-term risk, DBD is more volatile compared to STRF. This indicates higher risk in terms of short-term price fluctuations for DBD.Check STRF's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, ZM has a market cap of 26B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while ZM trades at $88.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas ZM's P/E ratio is 14.70. In terms of profitability, DBD's ROE is +0.11%, compared to ZM's ROE of +0.32%. Regarding short-term risk, DBD is less volatile compared to ZM. This indicates lower risk in terms of short-term price fluctuations for DBD.Check ZM's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, BSP has a market cap of 25.5B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while BSP trades at $38.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas BSP's P/E ratio is -380800.00. In terms of profitability, DBD's ROE is +0.11%, compared to BSP's ROE of +0.18%. Regarding short-term risk, DBD is more volatile compared to BSP. This indicates higher risk in terms of short-term price fluctuations for DBD.Check BSP's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, STRD has a market cap of 24.5B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while STRD trades at $74.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas STRD's P/E ratio is -0.76. In terms of profitability, DBD's ROE is +0.11%, compared to STRD's ROE of -0.61%. Regarding short-term risk, DBD is more volatile compared to STRD. This indicates higher risk in terms of short-term price fluctuations for DBD.Check STRD's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, STRK has a market cap of 22.4B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while STRK trades at $75.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas STRK's P/E ratio is -0.78. In terms of profitability, DBD's ROE is +0.11%, compared to STRK's ROE of -0.61%. Regarding short-term risk, DBD is less volatile compared to STRK. This indicates lower risk in terms of short-term price fluctuations for DBD.Check STRK's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, FICO has a market cap of 20.5B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while FICO trades at $949.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas FICO's P/E ratio is 23.89. In terms of profitability, DBD's ROE is +0.11%, compared to FICO's ROE of -0.33%. Regarding short-term risk, DBD is more volatile compared to FICO. This indicates higher risk in terms of short-term price fluctuations for DBD.Check FICO's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, SSNC has a market cap of 18.8B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while SSNC trades at $79.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas SSNC's P/E ratio is 12.49. In terms of profitability, DBD's ROE is +0.11%, compared to SSNC's ROE of +0.13%. Regarding short-term risk, DBD is more volatile compared to SSNC. This indicates higher risk in terms of short-term price fluctuations for DBD.Check SSNC's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, U has a market cap of 18.1B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while U trades at $41.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas U's P/E ratio is -78.11. In terms of profitability, DBD's ROE is +0.11%, compared to U's ROE of -0.19%. Regarding short-term risk, DBD is more volatile compared to U. This indicates higher risk in terms of short-term price fluctuations for DBD.Check U's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, GRABW has a market cap of 17B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while GRABW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas GRABW's P/E ratio is 0.22. In terms of profitability, DBD's ROE is +0.11%, compared to GRABW's ROE of +0.09%. Regarding short-term risk, DBD is less volatile compared to GRABW. This indicates lower risk in terms of short-term price fluctuations for DBD.Check GRABW's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, AZPN has a market cap of 16.7B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while AZPN trades at $264.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas AZPN's P/E ratio is 2403.00. In terms of profitability, DBD's ROE is +0.11%, compared to AZPN's ROE of -0.00%. Regarding short-term risk, DBD is more volatile compared to AZPN. This indicates higher risk in terms of short-term price fluctuations for DBD.Check AZPN's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, DT has a market cap of 16.1B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while DT trades at $55.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas DT's P/E ratio is 31.15. In terms of profitability, DBD's ROE is +0.11%, compared to DT's ROE of +0.06%. Regarding short-term risk, DBD is more volatile compared to DT. This indicates higher risk in terms of short-term price fluctuations for DBD.Check DT's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, PTC has a market cap of 15.7B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while PTC trades at $135.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas PTC's P/E ratio is 13.98. In terms of profitability, DBD's ROE is +0.11%, compared to PTC's ROE of +0.33%. Regarding short-term risk, DBD is more volatile compared to PTC. This indicates higher risk in terms of short-term price fluctuations for DBD.Check PTC's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, TYL has a market cap of 13.8B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while TYL trades at $337.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas TYL's P/E ratio is 29.07. In terms of profitability, DBD's ROE is +0.11%, compared to TYL's ROE of +0.09%. Regarding short-term risk, DBD is more volatile compared to TYL. This indicates higher risk in terms of short-term price fluctuations for DBD.Check TYL's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, DOCU has a market cap of 13.2B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while DOCU trades at $69.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas DOCU's P/E ratio is 17.14. In terms of profitability, DBD's ROE is +0.11%, compared to DOCU's ROE of +0.18%. Regarding short-term risk, DBD is more volatile compared to DOCU. This indicates higher risk in terms of short-term price fluctuations for DBD.Check DOCU's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, AUR has a market cap of 12.4B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while AUR trades at $6.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas AUR's P/E ratio is -13.15. In terms of profitability, DBD's ROE is +0.11%, compared to AUR's ROE of -0.43%. Regarding short-term risk, DBD is more volatile compared to AUR. This indicates higher risk in terms of short-term price fluctuations for DBD.Check AUR's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, MANH has a market cap of 12.3B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while MANH trades at $211.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas MANH's P/E ratio is 41.30. In terms of profitability, DBD's ROE is +0.11%, compared to MANH's ROE of +0.85%. Regarding short-term risk, DBD is more volatile compared to MANH. This indicates higher risk in terms of short-term price fluctuations for DBD.Check MANH's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, GWRE has a market cap of 12B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while GWRE trades at $144.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas GWRE's P/E ratio is 41.33. In terms of profitability, DBD's ROE is +0.11%, compared to GWRE's ROE of +0.10%. Regarding short-term risk, DBD is more volatile compared to GWRE. This indicates higher risk in terms of short-term price fluctuations for DBD.Check GWRE's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, BKI has a market cap of 11.9B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while BKI trades at $75.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas BKI's P/E ratio is 47.96. In terms of profitability, DBD's ROE is +0.11%, compared to BKI's ROE of +0.06%. Regarding short-term risk, DBD is more volatile compared to BKI. This indicates higher risk in terms of short-term price fluctuations for DBD.Check BKI's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, CHYM has a market cap of 11.6B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while CHYM trades at $30.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas CHYM's P/E ratio is -433.29. In terms of profitability, DBD's ROE is +0.11%, compared to CHYM's ROE of -0.01%. Regarding short-term risk, DBD is more volatile compared to CHYM. This indicates higher risk in terms of short-term price fluctuations for DBD.Check CHYM's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, FROG has a market cap of 11.2B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while FROG trades at $92.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas FROG's P/E ratio is 94.70. In terms of profitability, DBD's ROE is +0.11%, compared to FROG's ROE of -0.05%. Regarding short-term risk, DBD is less volatile compared to FROG. This indicates lower risk in terms of short-term price fluctuations for DBD.Check FROG's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, DAY has a market cap of 11.2B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while DAY trades at $69.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas DAY's P/E ratio is -73.54. In terms of profitability, DBD's ROE is +0.11%, compared to DAY's ROE of -0.06%. Regarding short-term risk, DBD is more volatile compared to DAY. This indicates higher risk in terms of short-term price fluctuations for DBD.Check DAY's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, GRAB has a market cap of 11.1B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while GRAB trades at $2.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas GRAB's P/E ratio is 20.16. In terms of profitability, DBD's ROE is +0.11%, compared to GRAB's ROE of +0.09%. Regarding short-term risk, DBD is more volatile compared to GRAB. This indicates higher risk in terms of short-term price fluctuations for DBD.Check GRAB's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, HUBS has a market cap of 11.1B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while HUBS trades at $216.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas HUBS's P/E ratio is 18.44. In terms of profitability, DBD's ROE is +0.11%, compared to HUBS's ROE of +0.08%. Regarding short-term risk, DBD is less volatile compared to HUBS. This indicates lower risk in terms of short-term price fluctuations for DBD.Check HUBS's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, FIG has a market cap of 11.1B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while FIG trades at $22.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas FIG's P/E ratio is 63.06. In terms of profitability, DBD's ROE is +0.11%, compared to FIG's ROE of -1.08%. Regarding short-term risk, DBD is less volatile compared to FIG. This indicates lower risk in terms of short-term price fluctuations for DBD.Check FIG's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, XM has a market cap of 11B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while XM trades at $18.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas XM's P/E ratio is -10.43. In terms of profitability, DBD's ROE is +0.11%, compared to XM's ROE of -0.52%. Regarding short-term risk, DBD is more volatile compared to XM. This indicates higher risk in terms of short-term price fluctuations for DBD.Check XM's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, CDAY has a market cap of 10.9B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while CDAY trades at $69.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas CDAY's P/E ratio is 2317.33. In terms of profitability, DBD's ROE is +0.11%, compared to CDAY's ROE of -0.06%. Regarding short-term risk, DBD is more volatile compared to CDAY. This indicates higher risk in terms of short-term price fluctuations for DBD.Check CDAY's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, PAYC has a market cap of 10.2B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while PAYC trades at $226.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas PAYC's P/E ratio is 21.94. In terms of profitability, DBD's ROE is +0.11%, compared to PAYC's ROE of +0.40%. Regarding short-term risk, DBD is more volatile compared to PAYC. This indicates higher risk in terms of short-term price fluctuations for DBD.Check PAYC's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, BSY has a market cap of 9.5B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while BSY trades at $32.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas BSY's P/E ratio is 25.65. In terms of profitability, DBD's ROE is +0.11%, compared to BSY's ROE of +0.24%. Regarding short-term risk, DBD is less volatile compared to BSY. This indicates lower risk in terms of short-term price fluctuations for DBD.Check BSY's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, ESTC has a market cap of 9B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while ESTC trades at $86.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas ESTC's P/E ratio is 33.70. In terms of profitability, DBD's ROE is +0.11%, compared to ESTC's ROE of +0.35%. Regarding short-term risk, DBD is more volatile compared to ESTC. This indicates higher risk in terms of short-term price fluctuations for DBD.Check ESTC's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, OCFT has a market cap of 8.6B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while OCFT trades at $7.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas OCFT's P/E ratio is -3.01. In terms of profitability, DBD's ROE is +0.11%, compared to OCFT's ROE of -0.03%. Regarding short-term risk, DBD is more volatile compared to OCFT. This indicates higher risk in terms of short-term price fluctuations for DBD.Check OCFT's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, YMM has a market cap of 8.5B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while YMM trades at $8.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas YMM's P/E ratio is 13.10. In terms of profitability, DBD's ROE is +0.11%, compared to YMM's ROE of +0.11%. Regarding short-term risk, DBD is more volatile compared to YMM. This indicates higher risk in terms of short-term price fluctuations for DBD.Check YMM's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, IDCC has a market cap of 8.3B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while IDCC trades at $323.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas IDCC's P/E ratio is 28.31. In terms of profitability, DBD's ROE is +0.11%, compared to IDCC's ROE of +0.27%. Regarding short-term risk, DBD is more volatile compared to IDCC. This indicates higher risk in terms of short-term price fluctuations for DBD.Check IDCC's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, GTLB has a market cap of 8.3B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while GTLB trades at $49.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas GTLB's P/E ratio is 48.26. In terms of profitability, DBD's ROE is +0.11%, compared to GTLB's ROE of -0.06%. Regarding short-term risk, DBD is more volatile compared to GTLB. This indicates higher risk in terms of short-term price fluctuations for DBD.Check GTLB's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, NATI has a market cap of 8B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while NATI trades at $59.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas NATI's P/E ratio is 44.44. In terms of profitability, DBD's ROE is +0.11%, compared to NATI's ROE of +0.12%. Regarding short-term risk, DBD is more volatile compared to NATI. This indicates higher risk in terms of short-term price fluctuations for DBD.Check NATI's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, SMAR has a market cap of 7.9B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while SMAR trades at $56.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas SMAR's P/E ratio is -806.71. In terms of profitability, DBD's ROE is +0.11%, compared to SMAR's ROE of -0.19%. Regarding short-term risk, DBD is more volatile compared to SMAR. This indicates higher risk in terms of short-term price fluctuations for DBD.Check SMAR's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, PCOR has a market cap of 7.7B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while PCOR trades at $51.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas PCOR's P/E ratio is 34.66. In terms of profitability, DBD's ROE is +0.11%, compared to PCOR's ROE of -0.03%. Regarding short-term risk, DBD is more volatile compared to PCOR. This indicates higher risk in terms of short-term price fluctuations for DBD.Check PCOR's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, PCTY has a market cap of 7.7B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while PCTY trades at $143.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas PCTY's P/E ratio is 17.25. In terms of profitability, DBD's ROE is +0.11%, compared to PCTY's ROE of +0.23%. Regarding short-term risk, DBD is more volatile compared to PCTY. This indicates higher risk in terms of short-term price fluctuations for DBD.Check PCTY's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, APPF has a market cap of 7.7B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while APPF trades at $214.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas APPF's P/E ratio is 37.72. In terms of profitability, DBD's ROE is +0.11%, compared to APPF's ROE of +0.31%. Regarding short-term risk, DBD is more volatile compared to APPF. This indicates higher risk in terms of short-term price fluctuations for DBD.Check APPF's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, ZETA has a market cap of 7.6B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while ZETA trades at $30.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas ZETA's P/E ratio is 35.58. In terms of profitability, DBD's ROE is +0.11%, compared to ZETA's ROE of -0.00%. Regarding short-term risk, DBD is less volatile compared to ZETA. This indicates lower risk in terms of short-term price fluctuations for DBD.Check ZETA's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, MAAS has a market cap of 7.3B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while MAAS trades at $16.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas MAAS's P/E ratio is -5.22. In terms of profitability, DBD's ROE is +0.11%, compared to MAAS's ROE of -0.39%. Regarding short-term risk, DBD is less volatile compared to MAAS. This indicates lower risk in terms of short-term price fluctuations for DBD.Check MAAS's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, CWAN has a market cap of 7.3B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while CWAN trades at $24.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas CWAN's P/E ratio is 43.09. In terms of profitability, DBD's ROE is +0.11%, compared to CWAN's ROE of -0.02%. Regarding short-term risk, DBD is more volatile compared to CWAN. This indicates higher risk in terms of short-term price fluctuations for DBD.Check CWAN's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, DSGX has a market cap of 6.6B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while DSGX trades at $77.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas DSGX's P/E ratio is 36.12. In terms of profitability, DBD's ROE is +0.11%, compared to DSGX's ROE of +0.12%. Regarding short-term risk, DBD is more volatile compared to DSGX. This indicates higher risk in terms of short-term price fluctuations for DBD.Check DSGX's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, DUOL has a market cap of 6.6B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while DUOL trades at $141.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas DUOL's P/E ratio is 16.81. In terms of profitability, DBD's ROE is +0.11%, compared to DUOL's ROE of +0.30%. Regarding short-term risk, DBD is more volatile compared to DUOL. This indicates higher risk in terms of short-term price fluctuations for DBD.Check DUOL's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, RNG has a market cap of 6.2B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while RNG trades at $71.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas RNG's P/E ratio is 15.72. In terms of profitability, DBD's ROE is +0.11%, compared to RNG's ROE of -0.21%. Regarding short-term risk, DBD is less volatile compared to RNG. This indicates lower risk in terms of short-term price fluctuations for DBD.Check RNG's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, NICE has a market cap of 6.2B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while NICE trades at $104.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas NICE's P/E ratio is 8.93. In terms of profitability, DBD's ROE is +0.11%, compared to NICE's ROE of +0.11%. Regarding short-term risk, DBD is more volatile compared to NICE. This indicates higher risk in terms of short-term price fluctuations for DBD.Check NICE's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, COUP has a market cap of 6.1B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while COUP trades at $80.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas COUP's P/E ratio is -17.99. In terms of profitability, DBD's ROE is +0.11%, compared to COUP's ROE of +0.00%. Regarding short-term risk, DBD is more volatile compared to COUP. This indicates higher risk in terms of short-term price fluctuations for DBD.Check COUP's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, CVLT has a market cap of 6B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while CVLT trades at $144.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas CVLT's P/E ratio is 33.08. In terms of profitability, DBD's ROE is +0.11%, compared to CVLT's ROE of +0.56%. Regarding short-term risk, DBD is less volatile compared to CVLT. This indicates lower risk in terms of short-term price fluctuations for DBD.Check CVLT's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, BLSH has a market cap of 5.8B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while BLSH trades at $38.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas BLSH's P/E ratio is 102.05. In terms of profitability, DBD's ROE is +0.11%, compared to BLSH's ROE of -0.45%. Regarding short-term risk, DBD is less volatile compared to BLSH. This indicates lower risk in terms of short-term price fluctuations for DBD.Check BLSH's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, PEGA has a market cap of 5.8B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while PEGA trades at $35.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas PEGA's P/E ratio is 19.47. In terms of profitability, DBD's ROE is +0.11%, compared to PEGA's ROE of +0.49%. Regarding short-term risk, DBD is more volatile compared to PEGA. This indicates higher risk in terms of short-term price fluctuations for DBD.Check PEGA's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, LYFT has a market cap of 5.7B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while LYFT trades at $15.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas LYFT's P/E ratio is 25.17. In terms of profitability, DBD's ROE is +0.11%, compared to LYFT's ROE of +1.16%. Regarding short-term risk, DBD is more volatile compared to LYFT. This indicates higher risk in terms of short-term price fluctuations for DBD.Check LYFT's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, DLB has a market cap of 5.5B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while DLB trades at $57.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas DLB's P/E ratio is 13.73. In terms of profitability, DBD's ROE is +0.11%, compared to DLB's ROE of +0.09%. Regarding short-term risk, DBD is more volatile compared to DLB. This indicates higher risk in terms of short-term price fluctuations for DBD.Check DLB's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, OTEX has a market cap of 5.5B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while OTEX trades at $22.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas OTEX's P/E ratio is 5.11. In terms of profitability, DBD's ROE is +0.11%, compared to OTEX's ROE of +0.28%. Regarding short-term risk, DBD is less volatile compared to OTEX. This indicates lower risk in terms of short-term price fluctuations for DBD.Check OTEX's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, NIQ has a market cap of 5.4B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while NIQ trades at $18.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas NIQ's P/E ratio is 50.58. In terms of profitability, DBD's ROE is +0.11%, compared to NIQ's ROE of -0.47%. Regarding short-term risk, DBD is more volatile compared to NIQ. This indicates higher risk in terms of short-term price fluctuations for DBD.Check NIQ's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, TTAN has a market cap of 5.3B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while TTAN trades at $55.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas TTAN's P/E ratio is 45.49. In terms of profitability, DBD's ROE is +0.11%, compared to TTAN's ROE of -0.08%. Regarding short-term risk, DBD is less volatile compared to TTAN. This indicates lower risk in terms of short-term price fluctuations for DBD.Check TTAN's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, NAVN has a market cap of 5.1B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while NAVN trades at $21.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas NAVN's P/E ratio is 328.46. In terms of profitability, DBD's ROE is +0.11%, compared to NAVN's ROE of -0.28%. Regarding short-term risk, DBD is less volatile compared to NAVN. This indicates lower risk in terms of short-term price fluctuations for DBD.Check NAVN's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, OCTV has a market cap of 5.1B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while OCTV trades at $18.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas OCTV's P/E ratio is 57.03. In terms of profitability, DBD's ROE is +0.11%, compared to OCTV's ROE of -0.27%. Regarding short-term risk, DBD is less volatile compared to OCTV. This indicates lower risk in terms of short-term price fluctuations for DBD.Check OCTV's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, BILL has a market cap of 4.7B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while BILL trades at $47.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas BILL's P/E ratio is 19.33. In terms of profitability, DBD's ROE is +0.11%, compared to BILL's ROE of -0.00%. Regarding short-term risk, DBD is more volatile compared to BILL. This indicates higher risk in terms of short-term price fluctuations for DBD.Check BILL's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, KVYO has a market cap of 4.6B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while KVYO trades at $15.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas KVYO's P/E ratio is 19.73. In terms of profitability, DBD's ROE is +0.11%, compared to KVYO's ROE of +0.01%. Regarding short-term risk, DBD is less volatile compared to KVYO. This indicates lower risk in terms of short-term price fluctuations for DBD.Check KVYO's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, DAVE has a market cap of 4.5B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while DAVE trades at $337.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas DAVE's P/E ratio is 27.16. In terms of profitability, DBD's ROE is +0.11%, compared to DAVE's ROE of +0.84%. Regarding short-term risk, DBD is less volatile compared to DAVE. This indicates lower risk in terms of short-term price fluctuations for DBD.Check DAVE's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, BULLW has a market cap of 4.5B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while BULLW trades at $2.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas BULLW's P/E ratio is 60.14. In terms of profitability, DBD's ROE is +0.11%, compared to BULLW's ROE of +0.04%. Regarding short-term risk, DBD is less volatile compared to BULLW. This indicates lower risk in terms of short-term price fluctuations for DBD.Check BULLW's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, GRND-WT has a market cap of 4.4B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while GRND-WT trades at $6.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas GRND-WT's P/E ratio is N/A. In terms of profitability, DBD's ROE is +0.11%, compared to GRND-WT's ROE of +3.57%. Regarding short-term risk, DBD is more volatile compared to GRND-WT. This indicates higher risk in terms of short-term price fluctuations for DBD.Check GRND-WT's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, BULL has a market cap of 4.4B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while BULL trades at $8.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas BULL's P/E ratio is -8.42. In terms of profitability, DBD's ROE is +0.11%, compared to BULL's ROE of +0.04%. Regarding short-term risk, DBD is less volatile compared to BULL. This indicates lower risk in terms of short-term price fluctuations for DBD.Check BULL's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, CVT has a market cap of 4.2B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while CVT trades at $8.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas CVT's P/E ratio is -40.57. In terms of profitability, DBD's ROE is +0.11%, compared to CVT's ROE of -0.06%. Regarding short-term risk, DBD is more volatile compared to CVT. This indicates higher risk in terms of short-term price fluctuations for DBD.Check CVT's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, WIX has a market cap of 4.1B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while WIX trades at $78.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas WIX's P/E ratio is 14.12. In terms of profitability, DBD's ROE is +0.11%, compared to WIX's ROE of +0.28%. Regarding short-term risk, DBD is less volatile compared to WIX. This indicates lower risk in terms of short-term price fluctuations for DBD.Check WIX's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, PYCR has a market cap of 4.1B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while PYCR trades at $22.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas PYCR's P/E ratio is -187.42. In terms of profitability, DBD's ROE is +0.11%, compared to PYCR's ROE of -0.05%. Regarding short-term risk, DBD is more volatile compared to PYCR. This indicates higher risk in terms of short-term price fluctuations for DBD.Check PYCR's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, WK has a market cap of 4B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while WK trades at $73.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas WK's P/E ratio is 25.49. In terms of profitability, DBD's ROE is +0.11%, compared to WK's ROE of -1.24%. Regarding short-term risk, DBD is more volatile compared to WK. This indicates higher risk in terms of short-term price fluctuations for DBD.Check WK's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, CCC has a market cap of 3.9B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while CCC trades at $6.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas CCC's P/E ratio is 16.79. In terms of profitability, DBD's ROE is +0.11%, compared to CCC's ROE of +0.02%. Regarding short-term risk, DBD is more volatile compared to CCC. This indicates higher risk in terms of short-term price fluctuations for DBD.Check CCC's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, YOU has a market cap of 3.8B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while YOU trades at $38.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas YOU's P/E ratio is 25.90. In terms of profitability, DBD's ROE is +0.11%, compared to YOU's ROE of +0.82%. Regarding short-term risk, DBD is less volatile compared to YOU. This indicates lower risk in terms of short-term price fluctuations for DBD.Check YOU's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, PWSC has a market cap of 3.8B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while PWSC trades at $22.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas PWSC's P/E ratio is -67.09. In terms of profitability, DBD's ROE is +0.11%, compared to PWSC's ROE of -0.02%. Regarding short-term risk, DBD is more volatile compared to PWSC. This indicates higher risk in terms of short-term price fluctuations for DBD.Check PWSC's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, FSLY has a market cap of 3.7B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while FSLY trades at $23.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas FSLY's P/E ratio is 50.77. In terms of profitability, DBD's ROE is +0.11%, compared to FSLY's ROE of -0.08%. Regarding short-term risk, DBD is less volatile compared to FSLY. This indicates lower risk in terms of short-term price fluctuations for DBD.Check FSLY's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, QTWO has a market cap of 3.7B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while QTWO trades at $58.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas QTWO's P/E ratio is 25.41. In terms of profitability, DBD's ROE is +0.11%, compared to QTWO's ROE of +0.14%. Regarding short-term risk, DBD is more volatile compared to QTWO. This indicates higher risk in terms of short-term price fluctuations for DBD.Check QTWO's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, MNDY has a market cap of 3.6B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while MNDY trades at $85.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas MNDY's P/E ratio is 19.17. In terms of profitability, DBD's ROE is +0.11%, compared to MNDY's ROE of +0.12%. Regarding short-term risk, DBD is less volatile compared to MNDY. This indicates lower risk in terms of short-term price fluctuations for DBD.Check MNDY's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, SRAD has a market cap of 3.6B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while SRAD trades at $12.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas SRAD's P/E ratio is 202.00. In terms of profitability, DBD's ROE is +0.11%, compared to SRAD's ROE of +0.02%. Regarding short-term risk, DBD is more volatile compared to SRAD. This indicates higher risk in terms of short-term price fluctuations for DBD.Check SRAD's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, AYX has a market cap of 3.5B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while AYX trades at $48.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas AYX's P/E ratio is -19.15. In terms of profitability, DBD's ROE is +0.11%, compared to AYX's ROE of -0.98%. Regarding short-term risk, DBD is more volatile compared to AYX. This indicates higher risk in terms of short-term price fluctuations for DBD.Check AYX's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, ENV has a market cap of 3.5B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while ENV trades at $63.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas ENV's P/E ratio is -13.21. In terms of profitability, DBD's ROE is +0.11%, compared to ENV's ROE of -0.36%. Regarding short-term risk, DBD is more volatile compared to ENV. This indicates higher risk in terms of short-term price fluctuations for DBD.Check ENV's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, PSFE-WT has a market cap of 3.5B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while PSFE-WT trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas PSFE-WT's P/E ratio is -0.13. In terms of profitability, DBD's ROE is +0.11%, compared to PSFE-WT's ROE of -0.33%. Regarding short-term risk, DBD is more volatile compared to PSFE-WT. This indicates higher risk in terms of short-term price fluctuations for DBD.Check PSFE-WT's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, INST has a market cap of 3.5B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while INST trades at $23.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas INST's P/E ratio is -63.78. In terms of profitability, DBD's ROE is +0.11%, compared to INST's ROE of -0.03%. Regarding short-term risk, DBD is more volatile compared to INST. This indicates higher risk in terms of short-term price fluctuations for DBD.Check INST's competition here

Diebold Nixdorf, Incorporated (NYSE: DBD) plays a significant role within the Technology sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DBD stands at 2.1B. In comparison, ZI has a market cap of 3.4B. Regarding current trading prices, DBD is priced at $63.20 on the NYSE, while ZI trades at $9.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DBD currently has a P/E ratio of 11.28, whereas ZI's P/E ratio is 77.92. In terms of profitability, DBD's ROE is +0.11%, compared to ZI's ROE of -0.41%. Regarding short-term risk, DBD is more volatile compared to ZI. This indicates higher risk in terms of short-term price fluctuations for DBD.Check ZI's competition here